DYRK1B and type 2 diabetes mellitus: Taking into consideration that (i) knockdown of Dyrk1b in diabetic mice improved blood glucose levels (Fig. 1H and I), (ii) glucose production in hepatocytes decreased after AZ191 treatment (Fig. 2G), and (iii) AZ191 treatment resulted in decreased occupancy of FOXO1 on chromatin (Fig. 5E and F), we propose AZ191 as a potential therapeutic candidate for T2DM.